Allakos ended the fourth quarter of 2024 with $80.8 million in cash, cash equivalents and investments. Allakos’ financial outlook, restructuring activities and estimated cash outlook as reported by ...
TipRanks on MSN6d
Allakos reports Q4 EPS 0c, consensus (18c)Allakos (ALLK) ended the fourth quarter of 2024 with $80.8M in cash, cash equivalents and investments. Published first on TheFly – the ultimate ...
Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU).
Explore Allakos stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ALLK. Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok ...
JMP Securities downgraded Allakos (ALLK) to Market Perform from Outperform without a price target after the company’s Phase 1 clinical trial of AK006 in chronic spontaneous urticaria did not ...
SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic ...
Allakos ended the fourth quarter of 2024 with $80.8 million in cash, cash equivalents and investments. Allakos’ financial outlook, restructuring activities and estimated cash outlook as reported ...
Allakos ended the fourth quarter of 2024 with $80.8 million in cash, cash equivalents and investments. Allakos' financial outlook, restructuring activities and estimated cash outlook as reported by ...
(MENAFN- GlobeNewsWire - Nasdaq) SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the“Company”) (Nasdaq: ALLK), a biotechnology company that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback